The Japanese owners of Vascutek in Inchinnan has announced an investment of £33 million for a major expansion of their headquarters.
The investment from Tokyo-based Terumo Corporation is to help drive further growth for the global medical device company.
Vascutek makes implants to help treat patients with aortic disease. Vascutek said these implants have helped to save or improve the lives of over 2 million patients in over 100 countries worldwide, over 90% of the products made at Inchinnan are exported.
Image Credit: Vascutek
The investment will be used to significantly scale up existing facilities at the site, including two new cleanrooms – a controlled manufacturing environment required for the production of the highest quality medical implants.
Other aspects of the investment include equipment for the cleanrooms and a new sterilisation suite. The first phase of the site development is due to start in April 2018 and is scheduled for completion in 2021.
Established in 1982, Vascutek employs around 800 staff at its Inchinnan base. It applies advanced and innovative technologies to develop its products which include an extensive range of sealed woven and knitted polyester grafts for peripheral, abdominal and cardiothoracic surgery, ePTFE grafts and a custom AAA stent graft system.
In the UK, the company has been granted 8 ‘Queen’s Awards for Enterprise’, with the most recent in 2016 for Innovation following the development of a unique surgical graft, Thoraflex™ Hybrid used in treating thoracic aortic disease and which has been successfully implanted in over 3,000 patients since its launch in 2012.
Paul Holbrook, President and CEO of Vascutek, said: “This is an extremely exciting time for the company as we look to secure further growth in the surgical grafts market. The investment from Terumo is testament to the quality, efficiency and excellent customer service delivered consistently by our team at Inchinnan and will allow us to further expand our business globally.
“The decision to invest in our manufacturing facilities sends a strong signal about the health of our company and our prospects for the future. It is an important milestone in our mission to create innovative products to the highest standard that benefit the lives of patients and their families across the world.”
Image Credit: Vascutek